Abstract:Abstract Aims/hypothesis Oral administration of antigen can induce immunological tolerance. Insulin is a key autoantigen in childhood type 1 diabetes. Here, oral insulin was given as antigen-specific immunotherapy before the onset of autoimmunity in children from age 6 months to assess its safety and immune response actions on immunity and the gut microbiome. Methods A phase I/II randomised controlled trial was performed in a single clinical study centre in Germany. Participants were 44 islet autoantibody-negative children aged 6 months to 2.99 years who had a first-degree relative with type 1 diabetes and a susceptible HLA DR4-DQ8 -containing genotype. Children were randomised 1:1 to daily oral insulin (7.5 mg with dose escalation to 67.5 mg) or placebo for 12 months using a web-based computer system. The primary outcome was immune efficacy pre-specified as induction of antibody or T cell responses to insulin and measured in a central treatment-blinded laboratory. Results Randomisation was performed in 44 children. One child in the placebo group was withdrawn after the first study visit and data from 22 insulin-treated and 21 placebo-treated children were analysed. Oral insulin was well tolerated with no changes in metabolic variables. Immune responses to insulin were observed in children who received both insulin (54.5%) and placebo (66.7%), and the trial did not demonstrate an effect on its primary outcome ( p = 0.54). In exploratory analyses, there was preliminary evidence that the immune response and gut microbiome were modified by the INS genotype Among children with the type 1 diabetes-susceptible INS genotype ( n = 22), antibody responses to insulin were more frequent in insulin-treated (72.7%) as compared with placebo-treated children (18.2%; p = 0.03). T cell responses to insulin were modified by treatment-independent inflammatory episodes. Conclusions/interpretation The study demonstrated that oral insulin immunotherapy in young genetically at-risk children was safe, but was not associated with an immune response as predefined in the trial primary outcome. Exploratory analyses suggested that antibody responses to oral insulin may occur in children with a susceptible INS genotype, and that inflammatory episodes may promote the activation of insulin-responsive T cells. Trial registration Clinicaltrials.gov NCT02547519 Funding The main funding source was the German Center for Diabetes Research (DZD e.V.) Graphical abstract

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes

Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy

Oral Delivery of Single-Chain Insulin (SCI-59) Analog by Bacterium-Like Particles (blps) Induces Oral Tolerance and Prevents Autoimmune Diabetes in NOD Mice.

Oral Delivery of Bi-Autoantigens by Bacterium-Like Particles (blps) Against Autoimmune Diabetes in NOD Mice.

Nano‐Targeted Delivery of Immune Therapeutics in type 1 Diabetes

Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes

Pre-clinical development of a tolerogenic peptide from glutamate decarboxylase as a candidate for antigen-specific immunotherapy in type 1 diabetes

Old Dog New Tricks: PLGA Microparticles As an Adjuvant for Insulin Peptide Fragment-Induced Immune Tolerance Against Type 1 Diabetes.

Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances

Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial

Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice

High Drug-Loading Gold Nanoclusters for Responsive Glucose Control in Type 1 Diabetes

Immunoprotection of Cellular Transplants for Autoimmune Type 1 Diabetes through Local Drug Delivery

Gold Nanoclusters for Controlled Insulin Release and Glucose Regulation in Diabetes.

Glucose-Responsive Gold Nanocluster-Loaded Microneedle Patch for Type 1 Diabetes Therapy.

Regulation of Blood Glucose Using Islets Encapsulated in a Melanin-Modified Immune-Shielding Hydrogel

Transfection of Pancreatic Islets Using Polyvalent DNA-functionalized Gold Nanoparticles.

CCL21 and beta-cell antigen releasing hydrogels as tolerance-inducing therapy in Type I diabetes

A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab

A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes